660838-05-1

Basic information

• Product Name: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER;5-(Boc-aMino)-2-Methylaniline
• CAS NO: 660838-05-1
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Mol File: 660838-05-1.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 308.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 13.57±0.70(Predicted)
• CAS DataBase Reference: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(660838-05-1)
• EPA Substance Registry System: (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(660838-05-1)

Safety Data

• Hazardous Substances Data: 660838-05-1(Hazardous Substances Data)

Usage

General Description

(3-Amino-4-methyl-phenyl)-carbamic acid tert-butyl ester is a chemical compound with the molecular formula C12H17N3O2. It is a tert-butyl ester of the carbamic acid derivative, which is commonly used as a protecting agent for amines during organic synthesis. It is a white to off-white crystalline powder that is slightly soluble in water and soluble in most organic solvents. (3-AMINO-4-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is often utilized in the pharmaceutical and agrochemical industries as a building block for the synthesis of various products, including pharmaceuticals, pesticides, and other organic compounds.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 95-80-7 4-methylbenzene-1,3-diamine 
• 2458-12-0 3-amino-p-toluic acid 
• 630410-29-6 (4-methyl-3-nitro-phenyl)-carbamic acid tert-butyl ester 
• 119-32-4 4-Methyl-3-nitroanilin 

Downstream Products

• 872092-02-9 tert-butyl [3-(8-methoxy-4-oxoquinazolin-3(4H)-yl)-4-methylphenyl]carbamate 
• 884000-87-7 tert-butyl {4-methyl-3-[(quinoxalin-6-ylcarbonyl)amino]phenyl}carbamate 
• 878745-39-2 tert-butyl 4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenylcarbamate 
• 946422-07-7 (3-{3-[6-(2,4-dimethoxy-benzylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-4-methyl-phenyl)carbamic acid tert-butyl ester 
• 946422-15-7 [4-methyl-3-(6-methylsulfanyl-[4,5']bipyrimidinyl-4'-ylamino)-phenyl]-carbamic acid tert-butyl ester 
• 1024583-35-4 (3-{[2-(3-ethyl-ureido)-benzothiazole-6-carbonyl]-amino}-4-methyl-phenyl)-carbamic acid tert-butyl ester 
• 1172621-17-8 tert-butyl 3-(2-(dimethylamino)acetamido)-4-mehtylphenylcarbamate 
• 1301267-30-0 tert-butyl 4-methyl-3-(3-phenylureido)phenylcarbamate 
• 1172621-18-9 tert-butyl 3-(2-(1,3-dioxoisoindolin-2-yl)acetamido)-4-methylphenylcarbamate 
• 1172621-34-9 methyl 2-(5-(tert-butoxycarbonylamino)-2-methylphenylamino)-2-oxoacetate 
• 1202759-64-5 C₂₄H₂₉N₅O₂ 
• 1318243-02-5 t-butyl 3-(4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamido)-4-methylphenylcarbamate 
• 1318243-03-6 N-(5-amino-2-methylphenyl)-4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1351237-52-9 N-(5-(3-(3-(2-cyanopropan-2-yl)phenyl)ureido)-2-methylphenyl)thieno[2,3-b]pyrazine-6-carboxamide 

Relevant articles and documents

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia

Starting from a dihydropyrimidopyrimidine core scaffold based compound 27 (GNF-7), we discovered a highly potent (ABL1: IC50 of 70 nM) and selective (S score (1) = 0.02) BCR-ABL inhibitor 18a (CHMFL-ABL-053). Compound 18a did not exhibit apparent inhibitory activity against c-KIT kinase, which is the common target of currently clinically used BCR-ABL inhibitors. Through significant suppression of the BCR-ABL autophosphorylation (EC50 about 100 nM) and downstream mediators such as STAT5, Crkl, and ERK's phosphorylation, 18a inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM), KU812 (GI50 = 25 nM), and MEG-01 (GI50 = 16 nM). A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats. A 50 mg/kg/day dosage treatment could almost completely suppress tumor progression in the K562 cells inoculated xenograft mouse model. As a potential useful drug candidate for CML, 18a is under extensive preclinical safety evaluation now.

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.